TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
Transcenta, Biologics, Antibody, Claudin 18.2
Partnering
We actively identify, evaluate and build new technology platforms through external collaborations and partnerships, commercialize key products in China with domestic pharmaceutical/biotech capabilities, and work with multinational pharmaceutical/biotech companies to accelerate overseas development and maximize the value of key products globally. If you want to share a partnership or technology opportunity with Transcenta, please contact bd@transcenta.com.
Global Partnership
Global clinical collaboration with BMS to evaluate Osemitamab (TST001) in combination with Opdivo® for 1L GC/GEJ cancer
Joint Venture
A Joint Venture with Alebund Pharmaceuticals to develop and commercialize TST004 in renal diseases in Greater China
Research Collaboration
Several research collaborations have been established with leading academic institutions worldwide, including the Dana-Farber Cancer Institute at Harvard Medical School, Peking University Cancer Hospital, Shanghai Pulmonary Hospital, Sun Yat-sen Hospital, Sun Yat-sen University and Shanghai Jiaotong University. The research collaborations cover Osemitamab (TST001), TST003 and TST005.
Technology-based Partnership
Co-development with Merck KGaA, leveraging our expertise in continuous bioprocessing technology to develop automated continuous downstream and other key enabling technologies.
Entered into a strategic partnership agreement for the marketing and promotion of oligonucleotide (mini-NNA) APIs and formulation manufacturing services with Apextide.
In-License
In-licensed Greater China rights (with ROFN for global) for all the bone disease franchise from Eli Lilly Transcenta will be responsible for global commercial manufacturing
Commercialization
A strategic cooperation with Tofflon for medium market development and sales.
